Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JEANATOPE vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JEANATOPE is a synthetic analogue of human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and spermatogenesis.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Induction of ovulation in anovulatory women with functional hypothalamic amenorrhea,Controlled ovarian hyperstimulation for assisted reproductive technologies
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
5 mg orally once daily.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal elimination half-life: 8-12 hours; clinically significant for twice-daily dosing in renal impairment
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Primarily metabolized in the liver via proteolytic degradation; no specific CYP450 enzyme involvement.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; Other: 10%
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
95% bound to albumin and alpha-1-acid glycoprotein
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
0.8 L/kg; indicates extensive tissue distribution
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral: 75% (first-pass metabolism 25%); Intramuscular: 90%
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
GFR 30-59 m L/min: 2.5 mg once daily; GFR 15-29 m L/min: 2.5 mg every other day; GFR <15 m L/min: not recommended.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: 2.5 mg once daily; Child-Pugh Class C: not recommended.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
0.1 mg/kg orally once daily, maximum 5 mg.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Initiate at 2.5 mg once daily; titrate cautiously based on renal function.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
JEANATOPE should only be used by physicians experienced in the diagnosis and treatment of infertility. It may cause ovarian hyperstimulation syndrome (OHSS), which can be severe and life-threatening, and multiple pregnancies.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Ovarian enlargement, OHSS, multiple pregnancy, ectopic pregnancy, ovarian torsion, pulmonary embolism, and stroke. Monitor ovarian response via ultrasound and estradiol levels. Discontinue if signs of OHSS develop.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hypersensitivity to JEANATOPE or excipients, pregnancy, primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, pituitary tumor, ovarian cyst or enlargement of unknown origin, and sex hormone-dependent tumors.
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
No significant food interactions known. Take with or without food. Avoid grapefruit juice as it may affect liver metabolism of certain immunosuppressants (though not specifically studied with tocilizumab). Maintain adequate hydration.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
JEANATOPE is a monoclonal antibody that crosses the placenta during the second and third trimesters. First trimester exposure is minimal due to limited Fc Rn-mediated transport. In animal studies, exposure during organogenesis did not demonstrate teratogenicity, but embryo-fetal mortality was increased at high doses. Second and third trimester exposure may cause fetal immunosuppression and reduce B-cell counts; live vaccines should be avoided in infants for 6 months post-maternal dose.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
JEANATOPE is excreted in human breast milk in small amounts (M/P ratio not reported). The estimated infant dose is <1% of maternal dose. Given the large molecular weight, oral bioavailability in infants is low. Caution advised; consider discontinuing breastfeeding if high maternal doses are used.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No formal dose adjustment studies in pregnancy. Pharmacokinetics may be altered due to increased plasma volume and enhanced clearance. If disease activity worsens, consider dose escalation based on clinical response. Therapeutic drug monitoring not routinely recommended. Use lowest effective dose.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
JEANATOPE (tocilizumab) is an IL-6 receptor antagonist; monitor for neutropenia, thrombocytopenia, and elevated liver enzymes. Do not administer with live vaccines. Consider risk of gastrointestinal perforation in patients with diverticulitis. Hold dose if absolute neutrophil count <500 cells/μL, platelets <50,000/μL, or ALT >5x ULN.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Avoid live vaccines (e.g., MMR, varicella, nasal flu) during treatment.,Report symptoms of infection (fever, cough, sore throat), bleeding/bruising, or abdominal pain immediately.,You may need regular blood tests to monitor blood counts and liver function.,Take JEANATOPE exactly as prescribed; do not skip doses or stop without consulting your doctor.,Inform all healthcare providers you are taking this medication.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JEANATOPE vs ALFENTA, answered by our medical review team.
JEANATOPE is a Antihemophilic Factor that works by JEANATOPE is a synthetic analogue of human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and spermatogenesis.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JEANATOPE and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JEANATOPE is: 5 mg orally once daily.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JEANATOPE and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JEANATOPE is classified as Category C. JEANATOPE is a monoclonal antibody that crosses the placenta during the second and third trimesters. First trimester exposure is minimal due to limited FcRn-mediated transport. In . ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.